PERSPECTIVE THERAPEUTICS INC (CATX)

US46489V3024 - Common Stock

2.85  +0.01 (+0.35%)

Premarket: 3 +0.15 (+5.26%)

PERSPECTIVE THERAPEUTICS INC

NYSEARCA:CATX (12/20/2024, 8:04:02 PM)

Premarket: 3 +0.15 (+5.26%)

2.85

+0.01 (+0.35%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%47.5%
Sales Q2Q%-83.11%
CRS4.44
6 Month-71.75%
Overview
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Ins Owners3.04%
Inst Owners57.25%
Market Cap192.18M
Shares67.43M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts81.25
Short Float %19.48%
Short Ratio6.27
IPO05-31 2002-05-31
Stock Screener Links
Screen Image

American Stock Exchange Stock Screener

Find more stocks on American Stock Exchange

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CATX Daily chart

Company Profile

Perspective Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Seattle, Washington and currently employs 116 full-time employees. The company went IPO on 2002-05-31. Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The firm has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The company is also developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The firm's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. The company has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.

Company Info

PERSPECTIVE THERAPEUTICS INC

2401 Elliott Avenue, Suite 320

Seattle WASHINGTON

P: 12066760900

Employees: 118

Website: https://www.perspectivetherapeutics.com/

CATX News

News Image3 days ago - Market News VideoBargain Hunters Take Note: Insider Cluster-Buying At CATX
News Image26 days ago - Perspective Therapeutics, Inc.Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...

News Imagea month ago - Perspective Therapeutics, Inc.Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested (2.5 and 5.0 mCi)Eight of...

News Imagea month ago - Perspective Therapeutics, Inc.Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...

News Imagea month ago - Perspective Therapeutics, Inc.Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated...

News Image2 months ago - Perspective Therapeutics, Inc.Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...

CATX Twits

Here you can normally see the latest stock twits on CATX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example